Aranzazu Fernandez-Martinez

Has grant

University of North Carolina, Lineberger Comprehensive Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

FSEOM

Open Date: 2017-10-01

Close Date:

Articles (7)

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (4)

Katherine Hoadley

Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES

View details

Terry Hyslop

Professor, Director of SKCC Center for Health Equity

Thomas Jefferson University

UNITED STATES

View details

Sara Lopez-Tarruella

ASSOCIATE PROFESSOR

Universidad Complutense de Madrid

SPAIN

View details

Gaia Griguolo

University of Padua

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Aranzazu Fernandez-Martinez

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (7)

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy.

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.

Collaborators (4)

Katherine Hoadley

Terry Hyslop

Sara Lopez-Tarruella

Gaia Griguolo

Make your next move.